Physician profile
David C Evans
NPI 1851517031
$175,459.33
in general payments reported to CMS, 2019-2025
14 companies · $17K in 2025
The $17K reported for 2025 was more than what 98% of Trauma Surgery providers received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40K · 2020: $27K · 2021: $5,831 · 2022: $15K · 2023: $24K · 2024: $46K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $40K · Travel and Lodging: $19K · Consulting Fee: $14K · Honoraria: $11K · Food and Beverage: $3,283 · Education: $18.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $39,600.00 |
| Travel and Lodging | $18,722.02 |
| Consulting Fee | $14,400.00 |
| Honoraria | $11,212.50 |
| Food and Beverage | $3,282.90 |
| Education | $18.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $106,784.32 | 2019-2025 | Smoflipid, Omegaven |
| Alcresta Therapeutics, INC. | $51,552.73 | 2019-2025 | Relizorb |
| Tetraphase Pharmaceuticals, INC. | $8,451.79 | 2019 | |
| Grifols Shared Services North America, INC. | $4,787.57 | 2019 | |
| Glaxosmithkline, LLC. | $2,000.00 | 2025 | |
| Becton, Dickinson and Company | $1,041.66 | 2020-2022 | |
| Covidien LP | $425.08 | 2019 | |
| Boston Scientific Corporation | $234.56 | 2024 | Spyglass Discover |
| Tela Bio, INC. | $107.72 | 2024 | Ovitex 2s |
| Smith+Nephew, INC. | $28.82 | 2025 | Collagenase Santyl |
| Merck Sharp & Dohme LLC | $18.09 | 2024 | Bridion |
| Portola Pharmaceuticals, LLC | $16.32 | 2020 | |
| Prytime Medical Devices, INC. | $10.67 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.